Aurum Biosciences is developing novel therapeutics and diagnostics in areas of unmet clinical need

The initial indications for Aurum’s ABL-101 injectable product include Acute Ischemic Stroke (AIS), Spinal Cord Injury (SCI).

Globally, AIS is a leading cause of death and disability with the majority of patients being unsuitable for treatment. ABL-101 could potentially deliver oxygen beyond the clot protecting tissue and increasing the opportunity to treat the stroke with other options. In conjunction with MRI imaging it could also provide stroke diagnostics.

There is currently no treatment capable of reversing damage to the spinal cord. Immediately following SCI, disruption to blood flow can lead to secondary irreversible damage. ABL-101 has the potential to protect this tissue and improve functional outcomes.

Aurum’s patented ABL 101 platform technology represents a paradigm shift in AIS and SCI management providing both therapeutic and diagnostic benefits.

Aurum is also developing this technology in other clinical indications such as inflammation, oncology and cardiovascular conditions.